(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 February 2011 (03.02.2011)

PCT

(10) International Publication Number
WO 2011/012719 A1

(51) **International Patent Classification**:
A61K 9/06 (2006.01) *A61K 9/00* (2006.01)
A61K 47/48 (2006.01)

(21) **International Application Number**:
PCT/EP2010/061160

(22) **International Filing Date**:
30 July 2010 (30.07.2010)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:

09167017.4	31 July 2009 (31.07.2009)	EP
09179337.2	15 December 2009 (15.12.2009)	EP
09179827.2	18 December 2009 (18.12.2009)	EP

(71) **Applicant** *(for all designated States except US)*: **ASCENDIS PHARMA AS** [DK/DK]; Tuborg Boulevard 12, DK-2900 Hellerup (DK).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **SPROGØE, Kennett** [DK/US]; 1982 West Bayshore Road #327, 94303 Palo Alto, CA (US). **CLEEMANN, Felix** [DE/DE]; Turnerstrasse 114, 69126 Heidelberg (DE). **HERSEL, Ulrich** [DE/DE]; Fritz-Frey-Strasse 2, 69121 Heidelberg (DE). **KADEN-VAGT, Silvia** [DE/DE]; Langgewann 79-81, 69121 Heidelberg (DE). **LEßMANN, Torben** [DE/DE]; Schimperstrasse 2, 68167 Mannheim (DE). **RAU, Harald** [DE/DE]; Schwarzwaldstr. 51/2, 69124 Heidelberg (DE). **WEGGE, Thomas** [DE/DE]; Kurfürstenanlage 43, 69115 Heidelberg (DE).

(74) **Agent**: **BÜCHEL, Edwin**; Isenbruck Bösl Hörschler LLP, Eastsite One, Seckenheimer Landstrasse 4, 68163 Mannheim (DE).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2011/012719 A1

(54) **Title**: LONG ACTING INSULIN COMPOSITION

(57) **Abstract**: The present invention relates to a pharmaceutical composition comprising an insulin compound in a concentration that is sufficient to maintain a therapeutically effective level of the insulin compound in blood plasma for at least 3 days characterized by having a pharmacokinetic profile in vivo with substantially no burst of the insulin compound. The present invention further relates to the use of an insulin compound for preparing said pharmaceutical composition as well as a kit of parts comprising said pharmaceutical composition.